![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ALEXION PURCHASES BIOPHARMACEUTICAL MANUFACTURING FACILITY IN RHODE ISLAND
ALEXION PURCHASES BIOPHARMACEUTICAL MANUFACTURING FACILITY IN RHODE ISLAND
Alexion Pharmaceuticals has purchased the former Dow manufacturing facility in Smithfield, Rhode Island. The biopharmaceutical
manufacturing facility will be used primarily to produce Soliris (eculizumab),
the company's lead product candidate, for Paroxysmal Nocturnal Hemoglobinuria
(PNH), an acquired genetic blood disorder, an Alexion release said. The financial
terms of the transaction were not disclosed.
Pharmabiz
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct